Gene interactions and pathways from curated databases and text-mining

◀ Back to MAPK6

MAPK6 — PPARG

Text-mined interactions from Literome

Goetze et al., J Cardiovasc Pharmacol 1999 : PPAR gamma ligands did not inhibit MAPK activation, suggesting a nuclear effect of these ligands downstream of MAPK ... We conclude that PPAR gamma ligands are potent inhibitors of VSMC migration pathways, dependent on MAPK and nuclear events
Samid et al., Clin Cancer Res 2000 (Neoplasms) : In support are the following observations : ( a ) the efficacy of phenylacetate as a cytostatic agent was correlated with pre-treatment levels of PPARgamma, as documented using established tumor lines and forced expression models ; ( b ) in responsive tumor cells, PPARgamma expression was up-regulated within 2-9 h of treatment preceding increases in p21waf1, a marker of cell cycle arrest ; ( c ) inhibition of mitogen activated protein kinase , a negative regulator of PPARgamma , enhanced drug activity ; and ( d ) phenylacetate interacted directly with the ligand binding site of PPARgamma and activated its transcriptional function
Watanabe et al., Biochem Biophys Res Commun 2003 : Furthermore, MAPK activation, achieved by overexpressing constitutively activated MEK1, inhibited PPAR gamma transcriptional activity
Muzio et al., Toxicology 2003 (Liver Neoplasms, Experimental) : The increase of protein phosphatase 2A induced by PPARgamma caused a decrease of MAPK , an intracellular signaling transduction pathway, as shown by evaluation of Erk1,2 and c-myc
Ghosh et al., Kidney Int 2003 : Using ciglitazone as the model compound, the mechanism of the antiproliferative effect of PPARgamma activators on MAPK and specific cell cycle regulatory proteins were examined by Western blot analysis and transfection studies
Ueta et al., Kidney Int 2004 : MAPK suppresses PPARgamma1 at the transcriptional level, and the reduction of PPARgamma1 in cultured rat mesangial cells under the high glucose condition induces phenotypic change and loss of contractile function
Chang et al., Kidney Int 2004 (MAP Kinase Signaling System) : Activation of PPAR-gamma by rosiglitazone inhibited AGE induced iNOS expression, nitrite release, and p38 MAPK activation in mesangial cells
Schaiff et al., J Clin Endocrinol Metab 2005 : Finally, we found that inhibition of p38 MAPK , which diminishes the activity of PPARgamma in trophoblasts, inhibited fatty acid uptake and blocked the PPARgamma- and RXR dependent increases in adipophilin and FATP4 expression, yet stimulated the expression of FATP1, FATP2, and FATP3
Ptasinska et al., FASEB J 2007 : PPARgamma activation by p38 MAPK may contribute to the anti-inflammatory and cytoprotective effects of NO* in the vasculature
Su et al., Physiol Genomics 2007 : Analysis of PPAR-gamma effects on DNA synthesis, formation of preneoplastic lesions, and activation of MAPK signaling in proximal and distal colonic epithelial cells in vivo indicates that PPAR-gamma regulates both tissue-specific and common responses within the proximal and distal colon
Zheng et al., Biol Chem 2007 : SB203580, a p38MAPK inhibitor, was able to inhibit the phosphorylation of p38MAPK , but did not reduce the expression of PPARgamma2
Xing et al., Journal of neuroinflammation 2008 (Encephalitis) : Our findings suggest that PPAR-gamma activation may involve differential regulation of p38 MAPK and of the PI3K/Akt pathway in the regulation of the inflammatory process
Yang et al., Life Sci 2010 : These results showed that PEDF promotes IL-10 expression at transcriptional level, and that this is achieved through the ERK2/p38MAPK dependent PPARgamma expression